Hikma Pharmaceuticals

Phone: +213 23 20 91 03

Web: https://www.hikma.com/

Type	Public
Traded as	LSE: HIK FTSE 250 Component
Industry	Pharmaceutical
Founded	1978 (1978)
Founder	Samih Darwazah
Headquarters	London, England, UK
Key people	Said Darwazah (chair­person)  Said Darwazah (CEO)
Products	Amoclan Prograf Suprax
Revenue	US$2,553 million (2021)
Operating income	US$632 million (2021)
Net income	US$420 million (2021)
Number of employees	8,700 (2022)
Website	www.hikma.com

We're helping to shape a healthier world that enriches all of our communities. Our Board is responsible for corporate governance and company performance while our Executive Committee manages the day-to-day business. The Committee meets regularly to provide organisational direction and take strategic business decisions. Our partners collaborate with us because of our reputation for quality, our strong brand recognition, and our US FDA-inspected manufacturing plants. Organisations we work with know they can rely on us to deliver consistently, in all our markets. We have always been committed to high standards of ethical conduct. In our business and in our dealings with other people. At the heart of this are our four values: Integrity. Excellence. Respect. Transparency. These shape the way our people think, work and behave. And ensure the sustainability of our company. In 2017, we achieved the highest ranking of any pharmaceutical company in the UK’s Institute of Directors' Good Governance Report.

For detailed contact information visit location pages below.